GHK-Cu is a copper-binding tripeptide that promotes collagen synthesis and remodelling through fibroblast activation; BPC-157 is a 15-amino-acid gastric peptide that drives angiogenesis through VEGFR2 and upregulates multiple growth factors.
Research reference only — all information on this page summarises peer-reviewed scientific literature and does not constitute medical advice. View full compound profiles: GHK-Cu · BPC-157
Mechanism Comparison
GHK-Cu (Gly-His-Lys–copper complex) binds Cu²⁺ with high affinity and signals fibroblasts to upregulate collagen I, collagen III, and elastin synthesis — acting as an endogenous matrikine that also stimulates VEGF and FGF-2 expression. BPC-157 acts through VEGFR2 activation and upregulates EGF, FGF, and growth hormone receptors, driving angiogenesis and fibroblast recruitment into the wound bed. GHK-Cu works primarily through extracellular matrix synthesis and remodelling; BPC-157 works primarily through vascular and growth-factor signalling.
Side-by-Side Attributes
| Attribute | GHK-Cu | BPC-157 |
|---|---|---|
| Structure | Copper-chelating tripeptide (Gly-His-Lys) | Synthetic 15-amino-acid pentadecapeptide |
| Molecular weight | ~340 Da (peptide alone) | ~1,419 Da |
| Primary mechanism | Fibroblast activation; collagen I/III synthesis; matrikine signalling | VEGFR2 agonism; EGF/FGF upregulation; angiogenesis |
| Administration routes in research | Topical (skin); SC; IV | IP, SC, IM, oral (rodent models) |
| Collagen synthesis effect | Direct (primary mechanism) | Indirect (via growth factor upregulation) |
| Angiogenesis effect | Indirect (via VEGF/FGF upregulation) | Direct (primary mechanism via VEGFR2) |
| Topical research evidence | Extensive cosmetic/dermal literature | Limited topical data; most research is systemic |
| GI tract research | Limited | Extensive (origin compound for gastric protection) |
| Regulatory status | Cosmetic ingredient (topical); 503A compound (systemic) | 503A Cat 2 (restricted, systemic) |
Key Research Points
- 1GHK-Cu has a much larger topical/dermal research literature — it is a well-characterised cosmetic active ingredient with published clinical data on wound healing, wrinkle reduction, and skin thickness, making it the appropriate tool for dermal research questions.
- 2BPC-157 has a larger systemic tissue repair literature across multiple organ systems (GI, musculoskeletal, CNS, cardiovascular) — most via injectable rodent protocols. Its gastric origin makes it particularly studied in intestinal permeability and IBD models.
- 3The two compounds address different phases of tissue repair: GHK-Cu drives ECM remodelling (collagen synthesis/organisation); BPC-157 drives vascular supply establishment (angiogenesis) and growth factor recruitment to the repair site.
- 4GHK-Cu is widely available as a cosmetic ingredient in topical formulations (not restricted for topical use); BPC-157 is restricted under 503A Cat 2 for systemic compounding use as of mid-2026.
- 5Combination research exists: because angiogenesis (BPC-157) and ECM deposition (GHK-Cu) are sequential but interdependent steps in tissue repair, some protocols have used both in parallel, similar to the BPC-157 / TB-500 co-administration rationale.
Frequently Asked Questions
What is the difference between GHK-Cu and BPC-157 for tissue repair research?
GHK-Cu (copper tripeptide) acts primarily through fibroblast activation and direct collagen I/III synthesis — it is a matrikine signal that also upregulates VEGF and FGF. BPC-157 acts primarily through VEGFR2 activation, driving angiogenesis and recruiting growth factors to the repair site. In tissue repair, GHK-Cu is stronger for ECM remodelling and collagen deposition; BPC-157 is stronger for vascular supply and growth factor recruitment. GHK-Cu also has extensive topical/dermal research data; BPC-157's literature is primarily systemic.
Does GHK-Cu have published clinical research?
Yes — GHK-Cu has published clinical data, primarily in the cosmetic dermatology literature. Controlled studies have demonstrated measurable improvements in wound healing, skin thickness, and wrinkle depth in human subjects using topical GHK-Cu formulations. This places it in a more clinically-studied position than most research peptides; however, its systemic (injectable) use remains investigational and not FDA-approved.
Which compound should be used for GI tract repair research — GHK-Cu or BPC-157?
BPC-157 is the appropriate choice for GI tract repair research. It was originally identified as a cytoprotective factor in human gastric juice and has an extensive published preclinical literature specifically on GI epithelial repair, gastric ulcer healing, intestinal anastomosis, and IBD models in rodents. GHK-Cu has limited published data on GI tissue specifically; the copper tripeptide literature is concentrated in dermal and wound-healing applications.
Deep Dive
For extended mechanism analysis, trial data, and regulatory context, see the full research article:
BPC-157 vs GHK-Cu: Tissue Repair Peptide Research Comparison →Full compound profile
GHK-Cu
Full compound profile
BPC-157